William D. Waddill - Jul 24, 2024 Form 4 Insider Report for Protagonist Therapeutics, Inc (PTGX)

Role
Director
Signature
/s/ Matthew Gosling, Attorney-in-Fact for William D. Waddill
Stock symbol
PTGX
Transactions as of
Jul 24, 2024
Transactions value $
-$216,960
Form type
4
Date filed
7/26/2024, 04:31 PM
Previous filing
Jun 11, 2024
Next filing
Sep 12, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PTGX Common Stock Options Exercise $103K +8K +66.67% $12.88 20K Jul 24, 2024 Direct
transaction PTGX Common Stock Sale -$320K -8K -40% $40.00 12K Jul 24, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PTGX Stock Option (right to buy) Options Exercise $0 -8K -50% $0.00 8K Jul 24, 2024 Common Stock 8K $12.88 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Sale of shares effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 10, 2023.
F2 These stock options are fully vested.